Oncoloxía médica
Servicio
Hospital Universitario de Jaén
Jaén, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario de Jaén (32)
2024
-
Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry
Archivos de Bronconeumologia
-
Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study
Journal of Nutrition, Health and Aging, Vol. 28, Núm. 8
-
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry
Lung Cancer, Vol. 190
-
Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis
Journal of Medical Economics, Vol. 27, Núm. 1, pp. 1379-1387
-
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study
Clinical and Translational Oncology, Vol. 26, Núm. 8, pp. 1896-1907
2023
2022
2021
-
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial
Molecular Oncology, Vol. 15, Núm. 1, pp. 43-56
-
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the thoracic tumor registry
PLoS ONE, Vol. 16, Núm. 6 June
-
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
BMC Cancer, Vol. 21, Núm. 1
-
Real-life use of ramucirumab in gastric cancer in Spain: The RAMIS study
Future Oncology, Vol. 17, Núm. 14, pp. 1777-1791
2020
-
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148
-
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
Lung Cancer, Vol. 150, pp. 62-69
-
Serum phospholipids fatty acids and breast cancer risk by pathological subtype
Nutrients, Vol. 12, Núm. 10, pp. 1-18
-
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation
Cancer Epidemiology, Vol. 67
2019
-
Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists
JOURNAL OF DRUG ASSESSMENT, Vol. 8, Núm. 1, pp. 62-69
-
Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)
Translational Lung Cancer Research, Vol. 8, Núm. 4, pp. 461-475
-
Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study
Scientific Reports, Vol. 9, Núm. 1
2018
-
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
European Journal of Cancer, Vol. 101, pp. 263-272
-
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study
BMC Cancer, Vol. 18, Núm. 1